Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland.
Clin Cancer Res. 2010 Jul 1;16(13):3442-51. doi: 10.1158/1078-0432.CCR-10-0052. Epub 2010 Jun 22.
We previously found that cellular FLICE-inhibitory protein (c-FLIP), caspase 8, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 (DR5) are major regulators of cell viability and chemotherapy-induced apoptosis in colorectal cancer. In this study, we determined the prognostic significance of c-FLIP, caspase 8, TRAIL and DR5 expression in tissues from patients with stage II and III colorectal cancer.
Tissue microarrays were constructed from matched normal and tumor tissue derived from patients (n = 253) enrolled in a phase III trial of adjuvant 5-fluorouracil-based chemotherapy versus postoperative observation alone. TRAIL, DR5, caspase 8, and c-FLIP expression levels were determined by immunohistochemistry.
Colorectal tumors displayed significantly higher expression levels of c-FLIP (P < 0.001), caspase 8 (P = 0.01), and DR5 (P < 0.001), but lower levels of TRAIL (P < 0.001) compared with matched normal tissue. In univariate analysis, higher TRAIL expression in the tumor was associated with worse overall survival (P = 0.026), with a trend to decreased relapse-free survival (RFS; P = 0.06), and higher tumor c-FLIP expression was associated with a significantly decreased RFS (P = 0.015). Using multivariate predictive modeling for RFS in all patients and including all biomarkers, age, treatment, and stage, we found that the model was significant when the mean tumor c-FLIP expression score and disease stage were included (P < 0.001). As regards overall survival, the overall model was predictive when both TRAIL expression and disease stage were included (P < 0.001).
High c-FLIP and TRAIL expression may be independent adverse prognostic markers in stage II and III colorectal cancer and might identify patients most at risk of relapse.
我们之前发现细胞型 FLICE 抑制蛋白(c-FLIP)、半胱天冬酶 8 和肿瘤坏死因子相关凋亡诱导配体(TRAIL)受体 2(DR5)是结直肠癌细胞活力和化疗诱导凋亡的主要调节因子。在这项研究中,我们确定了组织中 c-FLIP、半胱天冬酶 8、TRAIL 和 DR5 表达在 II 期和 III 期结直肠癌患者中的预后意义。
从参加 III 期试验的患者(n = 253)的匹配正常和肿瘤组织中构建组织微阵列,该试验比较了辅助 5-氟尿嘧啶为基础的化疗与术后单独观察的疗效。通过免疫组织化学测定 TRAIL、DR5、半胱天冬酶 8 和 c-FLIP 的表达水平。
与匹配的正常组织相比,结直肠肿瘤显示出明显更高的 c-FLIP(P < 0.001)、半胱天冬酶 8(P = 0.01)和 DR5(P < 0.001)表达水平,但 TRAIL 表达水平较低(P < 0.001)。在单因素分析中,肿瘤中 TRAIL 表达较高与总生存时间较差相关(P = 0.026),与无复发生存时间(RFS)呈下降趋势(P = 0.06),肿瘤 c-FLIP 表达较高与 RFS 显著降低相关(P = 0.015)。在所有患者中,使用包括所有生物标志物的 RFS 的多变量预测建模,包括年龄、治疗和分期,我们发现当包含平均肿瘤 c-FLIP 表达评分和疾病分期时,该模型具有显著意义(P < 0.001)。至于总生存时间,当包括 TRAIL 表达和疾病分期时,整体模型具有预测性(P < 0.001)。
高 c-FLIP 和 TRAIL 表达可能是 II 期和 III 期结直肠癌的独立不良预后标志物,并且可能识别出最有复发风险的患者。